Zacks.com on MSN1h
Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...
Vertex specializes in corporate tax compliance software, targeting a $22B global TAM with a focus on enterprise and SMB ...
Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...
In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...
1d
Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, ...
The polar vortex, a natural atmospheric phenomenon, influences global winter weather by circulating Arctic air. Its expansion ...
Hosted on MSN7d
Vertex's Pain Drug: Big Pharma's Next Major Success?Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...
stockhead on MSN3d
Vertex processes first ore for early gold RewardVertex Minerals (ASX:VTX) has processed first ore and begun commissioning of the high-grade Reward gold mine, with sales ...
The U.S. Bankruptcy Court for the Southern District of Texas allowed the company to exit bankruptcy as a privately-held company under the ownership of lenders. Those lenders include funds managed by ...
NDAQ:VRTX) Investors who lost money on Vertex Pharmaceuticals Incorporated should contact Levi & Korsinsky about an ongoing ...
It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback